Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8474)	1/25/1999 2:35:00 PM
From: opalapril	Read Replies (2) \| Respond to of 17367

While we wait... ...to see if it's caviar or cat food for Xoma investors, here's a small mystery, which may have been discussed before, that now takes on added magnitude in light of recent developments. From the Xoma FAQ (mystery in caps): What is an interim analysis? (6/98) Interim analyses monitor the conduct of the study and look for unexpected safety or efficacy issues. During a trial, the DSMB are the only people that are unblinded to the data (i.e. know which patients received drug and which placebo). All they report back to the company about results is that the study can continue, or that the study should be stopped early, because of an unexpected safety or futility problem, or alternatively, unexpectedly higher efficacy than planned for that study. Studies are not designed to stop at an interim analysis, BUT MANY DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDIES HAVE INTERIM ANALYSES IN CASE OF THE UNEXPECTED. So, guys and gals and doctors and patients -- and George -- what do you suppose was the "unexpected" warranting so many (3! 4?) interim analyses by the DSMB in '98?